New biotech Exalys, seek­ing to pre­vent post­op­er­a­tive delir­i­um, launch­es with $15 mil­lion in Se­ries A

An old group of for­mer col­leagues will be re­unit­ing to lead a new biotech ven­ture aimed at cul­ti­vat­ing a port­fo­lio to treat neu­roin­flam­ma­to­ry dis­or­ders.

Led by Rick Orr, who ran the biotech Ad­ynxx, the group is launch­ing the start­up Exalys on Thurs­day with $15 mil­lion in Se­ries A fund­ing from ven­ture firms Catalys Pa­cif­ic and Do­main As­so­ciates. The nascent com­pa­ny’s first project will fo­cus on pre­vent­ing post­op­er­a­tive delir­i­um, li­cens­ing a plat­form of EP4 re­cep­tors from Japan­ese phar­ma Ei­sai.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER